Compare WH & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WH | GRFS |
|---|---|---|
| Founded | 2017 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.2B |
| IPO Year | N/A | 2006 |
| Metric | WH | GRFS |
|---|---|---|
| Price | $80.03 | $8.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 2 |
| Target Price | ★ $94.04 | $10.15 |
| AVG Volume (30 Days) | ★ 996.7K | 485.7K |
| Earning Date | 02-11-2026 | 07-28-2022 |
| Dividend Yield | ★ 2.04% | 1.60% |
| EPS Growth | ★ 38.00 | N/A |
| EPS | ★ 4.33 | 0.64 |
| Revenue | $1,436,000,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $5.20 | $5.36 |
| Revenue Next Year | $5.89 | $5.15 |
| P/E Ratio | $18.51 | ★ $17.46 |
| Revenue Growth | 3.83 | ★ 7.31 |
| 52 Week Low | $69.21 | $6.19 |
| 52 Week High | $113.07 | $11.14 |
| Indicator | WH | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 44.66 |
| Support Level | $78.57 | $8.79 |
| Resistance Level | $81.48 | $9.40 |
| Average True Range (ATR) | 2.23 | 0.24 |
| MACD | 0.15 | -0.05 |
| Stochastic Oscillator | 80.54 | 12.18 |
As of June 30, 2025, Wyndham Hotels & Resorts operates 846,700 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 18% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands, as of the end of 2024. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 56% of total rooms, as of the end of 2024.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.